CGRP-Targeted Therapy for Episodic and Chronic Cluster Headache

التفاصيل البيبلوغرافية
العنوان: CGRP-Targeted Therapy for Episodic and Chronic Cluster Headache
المؤلفون: Shu-Ting Chen, Jr-Wei Wu
المصدر: Current Pain and Headache Reports. 26:667-675
بيانات النشر: Springer Science and Business Media LLC, 2022.
سنة النشر: 2022
مصطلحات موضوعية: Anesthesiology and Pain Medicine, Calcitonin Gene-Related Peptide, Migraine Disorders, Quality of Life, Antibodies, Monoclonal, Humans, Cluster Headache, Neurology (clinical), General Medicine
الوصف: Chronic cluster headache (CH) substantially affects patients' quality of life, and treatment remains challenging. The current article reviewed controlled studies for new treatment options targeting calcitonin gene-related peptide (CGRP) or its receptors in CH and discussed the current gaps and future directions for the treatment of chronic CH.Two anti-CGRP monoclonal antibodies (i.e., galcanezumab and fremanezumab) completed randomized-control trials for efficacy for the preventive treatment of episodic and chronic CH. Galcanezumab was effective for preventing episodic CH but not chronic CH. Fremanezumab was ineffective in preventing episodic and chronic CH. Studies for other anti-CGRP monoclonal antibodies and CGRP antagonists are still pending for results. There are no randomized controlled trials for CGRP-targeted therapies that showed efficacy for chronic CH prevention. The different responses to galcanezumab between episodic and chronic CH may be due to the study design, i.e., the allowance of concomitant preventive therapies in the chronic CH study but not in the episodic CH study. Another reason for the discrepancies is the different roles and sensitivity of CGRP in chronic CH.
تدمد: 1534-3081
1531-3433
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef1c949d0486b60666290fcdcd47fb5f
https://doi.org/10.1007/s11916-022-01070-6
حقوق: CLOSED
رقم الأكسشن: edsair.doi.dedup.....ef1c949d0486b60666290fcdcd47fb5f
قاعدة البيانات: OpenAIRE